There's actually nothing unusual going on with Pfizer's pharmaceutical business. The industry is highly competitive, capital-intensive, and driven by innovation. Unfortunately, research and ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

This earnings decrease was mainly driven by a one-time acquired in-process research and development charge related to Pfizer's licensing deal with 3SBio (TRSBF +10.00%). Without the impact of this ...

$43Bn Seagen acquisition positions Pfizer to dominate the $140Bn antibody-drug conjugate market. Numerous potential blockbusters launching pre-2030 should strengthen its oncology portfolio to offse ...

Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt. Stabilization of ...

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...